These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

391 related items for PubMed ID: 26350374

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Radio-Guided Surgery with a New-Generation β-Probe for Radiolabeled Somatostatin Analog, in Patients with Small Intestinal Neuroendocrine Tumors.
    Bertani E, Mattana F, Collamati F, Ferrari ME, Bagnardi V, Frassoni S, Pisa E, Mirabelli R, Morganti S, Fazio N, Fumagalli Romario U, Ceci F.
    Ann Surg Oncol; 2024 Jul; 31(7):4189-4196. PubMed ID: 38652200
    [Abstract] [Full Text] [Related]

  • 4. Can complementary 68Ga-DOTATATE and 18F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors?
    Has Simsek D, Kuyumcu S, Turkmen C, Sanlı Y, Aykan F, Unal S, Adalet I.
    J Nucl Med; 2014 Nov; 55(11):1811-7. PubMed ID: 25315243
    [Abstract] [Full Text] [Related]

  • 5. Radioguided Surgery With Gallium 68 Dotatate for Patients With Neuroendocrine Tumors.
    El Lakis M, Gianakou A, Nockel P, Wiseman D, Tirosh A, Quezado MA, Patel D, Nilubol N, Pacak K, Sadowski SM, Kebebew E.
    JAMA Surg; 2019 Jan 01; 154(1):40-45. PubMed ID: 30267071
    [Abstract] [Full Text] [Related]

  • 6. Clinical and Prognostic Value of PET/CT Imaging with Combination of 68Ga-DOTATATE and 18F-FDG in Gastroenteropancreatic Neuroendocrine Neoplasms.
    Zhang P, Yu J, Li J, Shen L, Li N, Zhu H, Zhai S, Zhang Y, Yang Z, Lu M.
    Contrast Media Mol Imaging; 2018 Jan 01; 2018():2340389. PubMed ID: 29681780
    [Abstract] [Full Text] [Related]

  • 7. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P, Ranade R, Ostwal V, Shrikhande SV, Goel M, Basu S.
    Nucl Med Commun; 2016 Oct 01; 37(10):1030-7. PubMed ID: 27243215
    [Abstract] [Full Text] [Related]

  • 8. The Correlation Between [68Ga]DOTATATE PET/CT and Cell Proliferation in Patients With GEP-NENs.
    Yu J, Li N, Li J, Lu M, Leal JP, Tan H, Su H, Fan Y, Zhang Y, Zhao W, Zhu H, Pomper MG, Zhou Y, Yang Z.
    Mol Imaging Biol; 2019 Oct 01; 21(5):984-990. PubMed ID: 30796708
    [Abstract] [Full Text] [Related]

  • 9. Dual Somatostatin Receptor/18F-FDG PET/CT Imaging in Patients with Well-Differentiated, Grade 2 and 3 Gastroenteropancreatic Neuroendocrine Tumors.
    Metser U, Nunez JE, Chan D, Kulanthaivelu R, Murad V, Santiago AT, Singh S.
    J Nucl Med; 2024 Oct 01; 65(10):1591-1596. PubMed ID: 39266292
    [Abstract] [Full Text] [Related]

  • 10. Larger Tumor Size and Elevated Serum Chromogranin A Levels Predict Metastatic Disease on DOTATATE Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors.
    Labora A, Shimizu T, Moore A, Premji A, Armstrong WR, Chen KY, Link J, Chan CS, Allen-Auerbach MS, Donahue TR.
    Ann Surg Oncol; 2024 Oct 01; 31(10):6875-6882. PubMed ID: 38909116
    [Abstract] [Full Text] [Related]

  • 11. Radioguided surgery with radiolabeled somatostatin analogs: not only in GEP-NETs.
    Cuccurullo V, Di Stasio GD, Mansi L.
    Nucl Med Rev Cent East Eur; 2017 Oct 01; 20(1):49-56. PubMed ID: 28218348
    [Abstract] [Full Text] [Related]

  • 12. Clinical Assessment of 177Lu-DOTATATE Quantification by Comparison of SUV-Based Parameters Measured on Both Post-PRRT SPECT/CT and 68Ga-DOTATOC PET/CT in Patients With Neuroendocrine Tumors: A Feasibility Study.
    Thuillier P, Maajem M, Schick U, Blanc-Beguin F, Hennebicq S, Metges JP, Salaun PY, Kerlan V, Bourhis D, Abgral R.
    Clin Nucl Med; 2021 Feb 01; 46(2):111-118. PubMed ID: 33234927
    [Abstract] [Full Text] [Related]

  • 13. Impact of initial imaging with gallium-68 dotatate PET/CT on diagnosis and management of patients with neuroendocrine tumors.
    Crown A, Rocha FG, Raghu P, Lin B, Funk G, Alseidi A, Hubka M, Rosales J, Lee M, Kennecke H.
    J Surg Oncol; 2020 Mar 01; 121(3):480-485. PubMed ID: 31853990
    [Abstract] [Full Text] [Related]

  • 14. Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTA-NOC PET-CT and 18F-FDG PET-CT: competitive or complimentary?
    Naswa N, Sharma P, Gupta SK, Karunanithi S, Reddy RM, Patnecha M, Lata S, Kumar R, Malhotra A, Bal C.
    Clin Nucl Med; 2014 Jan 01; 39(1):e27-34. PubMed ID: 24217539
    [Abstract] [Full Text] [Related]

  • 15. Defining the optimal segmentation method for measuring somatostatin receptor expressing tumor volume on 68 Ga-DOTATATE positron emission tomography/computed tomography to predict prognosis in patients with gastroenteropancreatic neuroendocrine tumors.
    Filizoglu N, Ozguven S, Akin Telli T, Ones T, Dede F, Turoglu HT, Erdil TY.
    Nucl Med Commun; 2024 Aug 01; 45(8):736-744. PubMed ID: 38745508
    [Abstract] [Full Text] [Related]

  • 16. Association between neuroendocrine tumors biomarkers and primary tumor site and disease type based on total 68Ga-DOTATATE-Avid tumor volume measurements.
    Tirosh A, Papadakis GZ, Millo C, Sadowski SM, Herscovitch P, Pacak K, Marx SJ, Yang L, Nockel P, Shell J, Green P, Keutgen XM, Patel D, Nilubol N, Kebebew E.
    Eur J Endocrinol; 2017 May 01; 176(5):575-582. PubMed ID: 28289088
    [Abstract] [Full Text] [Related]

  • 17. Is 18F-Fluorodeoxyglucose the Tracer of Choice for Functional Imaging of Neuroendocrine Tumors Grade 3? A Case Report.
    Lorusso M, Inzani F, Castaldi P, Menghi R, Schinzari G, Rindi G, Rufini V.
    Pancreas; 2018 Apr 01; 47(4):e20-e22. PubMed ID: 29521949
    [No Abstract] [Full Text] [Related]

  • 18. Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors.
    Deppen SA, Liu E, Blume JD, Clanton J, Shi C, Jones-Jackson LB, Lakhani V, Baum RP, Berlin J, Smith GT, Graham M, Sandler MP, Delbeke D, Walker RC.
    J Nucl Med; 2016 May 01; 57(5):708-14. PubMed ID: 26769865
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.